TapewireFind a company

person · Reporting owner

Boulding Mark Elliott

Disclosed activity across 1 company

Tapewire entity
21799
SEC CIK
0001578852

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
PTC THERAPEUTICS, INC.PTCT · Entity 3803EXEC. VP AND CLOOctober 09, 2026October 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PTC THERAPEUTICS, INC.

Report date October 09, 2026 · Filed October 13, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect105,272 Ending reported balance After 2026-10-09 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-10-09 · Exercise / conversion · Acquired 192 · Balance 105,464

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

Row 2 · 2026-10-09 · Sale · Disposed 192 · Balance 105,272

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.42 · Expires 2033-01-04Direct2,267 Reported balance After 2026-10-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-10-09 · Exercise / conversion · Disposed 192 · Balance 2,267

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 838 $65.72 $55,073.36
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 12

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,778

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F10 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.26 to $66.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 550 $64.44 $35,442.00
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 11

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,616

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 2,265 $39.42 $89,286.30
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 10

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,166

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 906 $66.63 $60,366.78
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 9

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.42 to $67.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 824 $65.73 $54,161.52
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 8

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,807

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.26 to $66.04 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 536 $64.43 $34,534.48
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 7

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,631

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 2,266 $39.42 $89,325.72
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 6

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,167

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,500 $67.15 $100,725.00
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.00 to $67.29 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 7,400 $66.44 $491,656.00
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,401

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.00 to $66.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 6,124 $65.47 $400,938.28
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,801

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.00 to $65.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 3,100 $64.43 $199,733.00
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,925

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 18,124 $39.42 $714,448.08
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 122,025

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
September 12, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 905 $0.00 Strike: $38.10 $0.00
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · derivative · entry 19

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,751

Underlying: Common Stock · 905 shares

Expires 2032-01-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F9 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.

Read SEC document
September 12, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 1,019 $0.00 Strike: $38.10 $0.00
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · derivative · entry 18

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,656

Underlying: Common Stock · 1,019 shares

Expires 2032-01-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F9 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.

Read SEC document
September 12, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 22,661 $0.00 Strike: $38.10 $0.00
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · derivative · entry 17

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,675

Underlying: Common Stock · 22,661 shares

Expires 2032-01-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F9 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.

Read SEC document
September 12, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 905 $61.21 $55,395.05
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 13

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.00 to $61.86 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 12, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 905 $38.10 $34,480.50
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 12

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,806

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
September 12, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,019 $61.31 $62,474.89
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 11

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.00 to $61.83 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 12, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 1,019 $38.10 $38,823.90
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 10

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,920

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
September 12, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 544 $62.09 $33,776.96
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 9

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.05 to $62.18 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 12, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 22,117 $61.33 $1,356,435.61
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 8

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,445

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.00 to $61.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 12, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 22,661 $38.10 $863,384.10
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 7

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,562

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
September 11, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 2,470 $0.00 Strike: $38.10 $0.00
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · derivative · entry 16

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,336

Underlying: Common Stock · 2,470 shares

Expires 2032-01-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F9 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.

Read SEC document
September 11, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 2,356 $0.00 Strike: $38.10 $0.00
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · derivative · entry 15

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,806

Underlying: Common Stock · 2,356 shares

Expires 2032-01-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F9 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.

Read SEC document
September 11, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 17,838 $0.00 Strike: $38.10 $0.00
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · derivative · entry 14

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,162

Underlying: Common Stock · 17,838 shares

Expires 2032-01-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F9 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.

Read SEC document
September 11, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 2,470 $61.00 $150,670.00
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 6

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.00 to $61.04 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 11, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 2,470 $38.10 $94,107.00
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,371

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
September 11, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 2,356 $61.00 $143,716.00
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.00 to $61.02 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 11, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 2,356 $38.10 $89,763.60
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,257

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
September 11, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 17,838 $61.00 $1,088,118.00
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.00 to $61.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 11, 2025 Filed Sep 15, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 17,838 $38.10 $679,627.80
Disclosure

SEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,739

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 20:30 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 2,813 $0.00 Strike: $25.69 $0.00
Disclosure

SEC source: 0001415889-25-022309 · form4-08192025_040801.xml · derivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,899

Underlying: Common Stock · 2,813 shares

Expires 2034-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F3 · derivative.exercise_date: This option was granted on February 14, 2024 and vests over four years, with 25% of the shares underlying the option vested on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 20:30 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 2,813 $48.58 $136,655.54
Disclosure

SEC source: 0001415889-25-022309 · form4-08192025_040801.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.24 to $49.11 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 20:30 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 2,813 $25.69 $72,265.97
Disclosure

SEC source: 0001415889-25-022309 · form4-08192025_040801.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,714

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
May 16, 2025 Filed May 19, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 883 $0.00 Strike: $25.69 $0.00
Disclosure

SEC source: 0001415889-25-013661 · form4-05192025_050501.xml · derivative · entry 6

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,712

Underlying: Common Stock · 883 shares

Expires 2034-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F4 · derivative.exercise_date: This option was granted on February 14, 2024 and vests over four years, with 25% of the shares underlying the option vested on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.

Read SEC document
May 16, 2025 Filed May 19, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 883 $46.02 $40,635.66
Disclosure

SEC source: 0001415889-25-013661 · form4-05192025_050501.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $46.00 to $46.19 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 16, 2025 Filed May 19, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 883 $25.69 $22,684.27
Disclosure

SEC source: 0001415889-25-013661 · form4-05192025_050501.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
May 15, 2025 Filed May 19, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 1,929 $0.00 Strike: $25.69 $0.00
Disclosure

SEC source: 0001415889-25-013661 · form4-05192025_050501.xml · derivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,595

Underlying: Common Stock · 1,929 shares

Expires 2034-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F4 · derivative.exercise_date: This option was granted on February 14, 2024 and vests over four years, with 25% of the shares underlying the option vested on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.

Read SEC document
May 15, 2025 Filed May 19, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,929 $46.18 $89,081.22
Disclosure

SEC source: 0001415889-25-013661 · form4-05192025_050501.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $46.00 to $46.61 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 15, 2025 Filed May 19, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 1,929 $25.69 $49,556.01
Disclosure

SEC source: 0001415889-25-013661 · form4-05192025_050501.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,830

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
March 12, 2025 Filed Mar 14, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 2,395 $0.00 Strike: $33.02 $0.00
Disclosure

SEC source: 0001415889-25-008141 · form4-03142025_050301.xml · derivative · entry 6

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,395 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F4 · derivative.exercise_date: Currently exercisable.

Read SEC document
March 12, 2025 Filed Mar 14, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 13,126 $0.00 Strike: $33.02 $0.00
Disclosure

SEC source: 0001415889-25-008141 · form4-03142025_050301.xml · derivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,126 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F4 · derivative.exercise_date: Currently exercisable.

Read SEC document
March 12, 2025 Filed Mar 14, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 2,395 $53.23 $127,485.85
Disclosure

SEC source: 0001415889-25-008141 · form4-03142025_050301.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to 53.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 12, 2025 Filed Mar 14, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 2,395 $33.02 $79,082.90
Disclosure

SEC source: 0001415889-25-008141 · form4-03142025_050301.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,296

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
March 12, 2025 Filed Mar 14, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 13,126 $53.31 $699,747.06
Disclosure

SEC source: 0001415889-25-008141 · form4-03142025_050301.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to 53.71 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 12, 2025 Filed Mar 14, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 13,126 $33.02 $433,420.52
Disclosure

SEC source: 0001415889-25-008141 · form4-03142025_050301.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,027

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
March 11, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 1,719 $0.00 Strike: $33.02 $0.00
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · derivative · entry 16

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,395

Underlying: Common Stock · 1,719 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

F8 · derivative.exercise_date: Currently exercisable.

Read SEC document
March 11, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 5,662 $0.00 Strike: $33.02 $0.00
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · derivative · entry 15

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,126

Underlying: Common Stock · 5,662 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

F8 · derivative.exercise_date: Currently exercisable.

Read SEC document
March 11, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,719 $53.01 $91,124.19
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 11

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $37.30 to $38.20 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 11, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 1,719 $33.02 $56,761.38
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 10

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,620

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.